Table 4.
Factors associated with virologic suppression (HIV-RNA <400 copies/ml) at 48 weeks of single boosted PI-based HAART (N=83)
| Variables* | Total patients N |
Univariate analysis OR (95% CI) |
p value | Multivariate analysis OR (95% CI) |
p value |
|---|---|---|---|---|---|
| Sex | |||||
| -male | 39 | 1 | |||
| -female | 44 | 0.57 (0.24,1.37) | 0.209 | ||
| Age in years at start of PI-based HAART | 83 | 0.92 (0.81,1.05) | 0.202 | 0.78 (0.65,0.93) | 0.007 |
| Weight for age z-score at start of PI-based HAART |
71 | 1.55 (1.09,2.21) | 0.014 | 1.71 (1.09,2.69) | 0.020 |
| CD4 count at starting PI-based HAART | |||||
| - Unavailable | 18 | 4.94 (1.52,16.0) | 0.089 | ||
| - <200 cells/mm3 | 20 | 1 | |||
| - ≥200 cells/mm3 | 45 | 6.00 (1.47,24.5) | 0.138 | ||
| HIV-RNA log10 copies/ml at start of PI-based HAART |
|||||
| - Unavailable | 40 | 3.00 (1.08,8.32) | 0.672 | 5.84 (1.47,23.28) | 0.423 |
| - <10000 | 16 | 6.00 (1.50,23.99) | 0.050 | 12.56 (1.93,81.75) | 0.049 |
| - ≥10000 | 27 | 1 | 1 | ||
| Years on NNRTI-based HAART before switching to PI-based HAART |
83 | 1.51 (1.11,2.05) | 0.008 | 1.84 (1.19,2.85) | 0.006 |
| WHO stage at start of PI-based HAART | |||||
| - Stage 1 or 2 | 30 | 1 | |||
| - Stage 3 | 30 | 0.48 (0.16,1.48) | 0.695 | ||
| - Stage 4 | 22 | 0.58 (0.21,1.62) | 0.365 | ||
| PI type | |||||
| - IDV/r | 10 | 0.31 (0.07,1.28) | |||
| - LPV/r | 72 | 1 | 0.105 |
OR (95%CI): odds ratio (95% confidence interval); AZT: zidovudine; 3TC: lamivudine; ddl: didanosine; d4T: stavudine; IDV/r: indinavir/ritonavir; LPV/r: lopinavir/ritonavir
*
Exposure to mono/dual antiretroviral regimens before first-line HAART, and NRTI combination used in PI-based regimen, and hemoglobin at start of PI-based HAART had no association with virologic suppression by univariate analysis (all p>0.10; data not shown)